WallStSmart

Avadel Pharmaceuticals PLC (AVDL)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 5760% more annual revenue ($14.56B vs $248.52M). AVDL leads profitability with a -0.0% profit margin vs -2.0%. AVDL appears more attractively valued with a PEG of 0.07. VTRS earns a higher WallStSmart Score of 48/100 (D+).

AVDL

Hold

41

out of 100

Grade: D

Growth: 4.3Profit: 2.5Value: 8.3Quality: 5.5
Piotroski: 3/9Altman Z: -5.40

VTRS

Hold

48

out of 100

Grade: D+

Growth: 3.3Profit: 2.5Value: 8.3Quality: 4.5
Piotroski: 4/9Altman Z: 0.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVDLUndervalued (+70.6%)

Margin of Safety

+70.6%

Fair Value

$73.50

Current Price

$21.64

$51.86 discount

UndervaluedFair: $73.50Overvalued
VTRSUndervalued (+33.6%)

Margin of Safety

+33.6%

Fair Value

$24.30

Current Price

$17.17

$7.13 discount

UndervaluedFair: $24.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVDL1 strengths · Avg: 10.0/10
PEG RatioValuation
0.0710/10

Growing faster than its price suggests

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1510/10

Growing faster than its price suggests

Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Areas to Watch

AVDL4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.5%4/10

0.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-2.0%2/10

ROE of -2.0% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-2.0%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : AVDL

The strongest argument for AVDL centers on PEG Ratio. PEG of 0.07 suggests the stock is reasonably priced for its growth.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.15 suggests the stock is reasonably priced for its growth.

Bear Case : AVDL

The primary concerns for AVDL are Revenue Growth, EPS Growth, Operating Margin.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

AVDL carries more volatility with a beta of 1.63 — expect wider price swings.

VTRS is growing revenue faster at 8.1% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (48/100 vs 41/100). AVDL offers better value entry with a 70.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Avadel Pharmaceuticals PLC

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.

Visit Website →

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?